Inari Medical, Inc. (NARI)
- Previous Close
43.84 - Open
43.97 - Bid 31.18 x 200
- Ask 43.79 x 400
- Day's Range
42.76 - 44.28 - 52 Week Range
36.73 - 69.40 - Volume
1,215,297 - Avg. Volume
883,468 - Market Cap (intraday)
2.545B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.99 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
64.93
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
www.inarimedical.comRecent News: NARI
View MorePerformance Overview: NARI
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NARI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NARI
View MoreValuation Measures
Market Cap
2.54B
Enterprise Value
2.47B
Trailing P/E
--
Forward P/E
208.33
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.61
Price/Book (mrq)
6.00
Enterprise Value/Revenue
4.51
Enterprise Value/EBITDA
1.58k
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.42%
Return on Assets (ttm)
-2.14%
Return on Equity (ttm)
-13.28%
Revenue (ttm)
547.47M
Net Income Avi to Common (ttm)
-57.05M
Diluted EPS (ttm)
-0.99
Balance Sheet and Cash Flow
Total Cash (mrq)
109.67M
Total Debt/Equity (mrq)
7.82%
Levered Free Cash Flow (ttm)
84.18M